Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$133.36

(0.00%)

11:41
04/19/18
04/19
11:41
04/19/18
11:41

FDA advisers vote in favor of approval for GW Pharmaceuticals cannabidiol

The FDA advisory committee voted 13-0 that the benefit-risk profile of cannabidiol is favorable for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years of age and older, according to various media reports of the panel meeting.

  • 19

    Apr

  • 21

    May

  • 27

    Jun

GWPH GW Pharmaceuticals
$133.36

(0.00%)

12/29/17
LEER
12/29/17
NO CHANGE
LEER
Outperform
GW filing acceptance, FDA panel in line with expectations, says Leerink
Leerink analyst Paul Matteis said the FDA accepting the Epidiolex new drug application and granting of priority review were in line with expectations given the three positive late-stage studies and the unmet need for the two rare orphan epilepsies. The analyst thinks an Advisory Committee was likely given that Epidiolex is a plant-derived cannabinoid drug seeking a primarily pediatric indication. Matteis yesterday reiterated an Overweight rating on shares of GW Pharmaceuticals.
01/23/18
LEER
01/23/18
NO CHANGE
Target $153
LEER
Outperform
Leerink cautiously optimistic ahead of GW Pharmaceuticals CBDV Phase 2 data
Leerink analyst Paul Matteis reiterates an Outperform rating on GW Pharmaceuticals, while lowering his price target on the shares to $153 from $154, ahead of CBDV Phase II data in partial-onset seizures in Q1. While he acknowledges that is difficult to garner conviction in the Phase 2, his analysis of pre-clinical results - compared side-by-side to cannabidiol - instills him with "cautious optimism" on the program, while he believes that the little credit priced into the stock for CBDV sets up an upside skewed risk/reward on the upcoming data readout this quarter.
02/06/18
CANT
02/06/18
NO CHANGE
Target $192
CANT
Overweight
GW Pharmaceuticals price target lowered to $192 from $208 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros lowered his price target for GW Pharmaceuticals to $192 following the company's Q1 financial results and recent equity raise. The analyst, however, believes the shares remain "significantly undervalued," based on his assessment of Epidiolex's opportunity in treating orphan pediatric epileptic conditions. He reiterates an Overweight rating on GW.
02/22/18
CANT
02/22/18
NO CHANGE
Target $192
CANT
Overweight
GW Pharmaceuticals shares could recover quickly, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros believes GW Pharmaceuticals shares could recover quickly from the selloff on the negative results with GWP42006 in adult patients with focal seizures. The analyst highlights the announcement of an advisory committee hearing for Epidiolex on April 18. The "clear near-term focus" is the successful commercialization of Epidiolex for pediatric pharmacoresistant seizures upon potential approval in the second half of 2018, Piros tells investors in a research note. He keeps an Overweight rating on GW shares with a $192 price target.

TODAY'S FREE FLY STORIES

RHT

Red Hat

$141.62

-1.17 (-0.82%)

14:49
09/19/18
09/19
14:49
09/19/18
14:49
Options
Red Hat options imply 12.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

HKMPY

Hikma

$0.00

(0.00%)

14:47
09/19/18
09/19
14:47
09/19/18
14:47
Conference/Events
Hikma has a conference call hosted by JPMorgan »

JPMorgan Analyst Gordon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

MS

Morgan Stanley

$49.09

1.22 (2.55%)

14:45
09/19/18
09/19
14:45
09/19/18
14:45
Options
Morgan Stanley call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 02

    Oct

FB

Facebook

$162.94

2.63 (1.64%)

14:42
09/19/18
09/19
14:42
09/19/18
14:42
Periodicals
Facebook user terms not yet in line with EU consumer laws, Reuters says »

Facebook may be slapped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

IPSEY

Ipsen

$0.00

(0.00%)

14:40
09/19/18
09/19
14:40
09/19/18
14:40
Conference/Events
Ipsen has a conference call hosted by JPMorgan »

JPMorgan Analyst Vosser…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

SIEN

Sientra

$23.85

-0.3 (-1.24%)

14:40
09/19/18
09/19
14:40
09/19/18
14:40
Hot Stocks
SEC charges Sientra, former CEO with misleading investors »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 15

    Nov

14:35
09/19/18
09/19
14:35
09/19/18
14:35
General news
Fed Policy Outlook: by this time next week »

Fed Policy Outlook: by…

DRE

Duke Realty

$28.36

-0.35 (-1.22%)

14:29
09/19/18
09/19
14:29
09/19/18
14:29
Hot Stocks
Duke Realty VP Peter Harrington sells almost 17K shares »

Duke Realty VP Peter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXGBY

Hexagon AB

$0.00

(0.00%)

14:25
09/19/18
09/19
14:25
09/19/18
14:25
Conference/Events
Hexagon AB management to meet with RBC Capital »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

WMB

Williams

$28.14

0.05 (0.18%)

14:25
09/19/18
09/19
14:25
09/19/18
14:25
Hot Stocks
Williams requests FERC permission to place Atlantic Sunrise into full service »

Williams reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEPT

Neptune Technologies

$4.93

0.675 (15.86%)

14:25
09/19/18
09/19
14:25
09/19/18
14:25
Options
Neptune Technologies call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$162.44

5.8 (3.70%)

14:18
09/19/18
09/19
14:18
09/19/18
14:18
Recommendations
Alibaba analyst commentary  »

Stifel still confident in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/19/18
09/19
14:17
09/19/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/19/18
09/19
14:16
09/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPOT

Spotify

$169.33

-6.1 (-3.48%)

14:16
09/19/18
09/19
14:16
09/19/18
14:16
Periodicals
Spotify accused of ' fostering a negative work culture for women,' Verge says »

Music streaming company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$162.49

5.85 (3.73%)

14:13
09/19/18
09/19
14:13
09/19/18
14:13
Periodicals
Alibaba no longer plans to bring 1M jobs to U.S. in wake of trade war, CNBC says »

Alibaba founder and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

SAFM

Sanderson Farms

$100.90

-2.04 (-1.98%)

14:09
09/19/18
09/19
14:09
09/19/18
14:09
Hot Stocks
Sanderson Farms reports on impact to operations from Hurricane Florence »

Sanderson Farms reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 06

    Nov

14:08
09/19/18
09/19
14:08
09/19/18
14:08
Conference/Events
RBC Capital internet analyst to hold a luncheon »

Internet Analyst Mahaney…

14:06
09/19/18
09/19
14:06
09/19/18
14:06
Conference/Events
RBC Capital multi-industry analyst to hold group luncheon »

Multi-Industry Analyst…

14:04
09/19/18
09/19
14:04
09/19/18
14:04
Conference/Events
RBC Capital biotech analysts to hold a group breakfast »

Biotech Gene Therapy…

CZR

Caesars

$10.90

0.1 (0.93%)

14:00
09/19/18
09/19
14:00
09/19/18
14:00
Options
Caesars option volume is 2X daily average and calls lead puts 10:1 »

Caesars option volume is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$0.00

(0.00%)

, LLY

Eli Lilly

$105.83

-1.06 (-0.99%)

13:51
09/19/18
09/19
13:51
09/19/18
13:51
Initiation
Elanco, Eli Lilly initiated  »

Elanco initiated with a…

ELAN

Elanco

$0.00

(0.00%)

LLY

Eli Lilly

$105.83

-1.06 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 01

    Oct

  • 04

    Oct

  • 20

    Sep

LFUS

Littelfuse

$204.06

-9.68 (-4.53%)

13:41
09/19/18
09/19
13:41
09/19/18
13:41
Recommendations
Littelfuse analyst commentary  »

Use weakness to buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

MRK

Merck

$70.16

-0.26 (-0.37%)

, BMY

Bristol-Myers

$60.93

-0.55 (-0.89%)

13:36
09/19/18
09/19
13:36
09/19/18
13:36
Periodicals
Merck cuts key cancer drug price for China launch, Caixin reports »

Merck (MRK) will cut the…

MRK

Merck

$70.16

-0.26 (-0.37%)

BMY

Bristol-Myers

$60.93

-0.55 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

GLUU

Glu Mobile

$7.30

-0.285 (-3.76%)

13:35
09/19/18
09/19
13:35
09/19/18
13:35
Options
Glu Mobile put volume heavy and directionally bearish »

Bearish flow noted in Glu…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.